Get the content you want anytime you want.
REGISTER NOW | SIGN IN
ARTICLE

Guidelines to Caring for Patients With Sepsis: Promise or Progress?

AUG 08, 2017 | JESSICA BURCHETTE, PHARMD, BCPS, AND DAVID CLUCK, PHARMD, BCPS, AAHIVP
The concept of “double coverage” with antimicrobials in critically ill patients has been the subject of debate for many years and has become essentially clinician-specific. The 2016 update suggests the use of empiric combination therapy in patients with septic shock; however, the evidence for this recommendation is weak, with little sup­port found in randomized controlled clinical trials. The importance of combination therapy is emphasized by the heightened risk of mortality with inadequate coverage.13

Clinicians may experience a certain sense of comfort in initiating empiric combination antimicrobial therapy in any patient, not just in those who are critically ill. However, this sense can be fallacious and should be off­set somewhat by the ques­tionable benefit that double coverage imparts to patients who have pathogens that are resistant to multiple drugs. Organisms that are resistant to beta-lactams are also likely to be resistant to a second, added agent, such as a fluo­roquinolone or an aminogly­coside; even if the resistance is not present, the second agent may simply provide no benefit.14 Although many attempts have been made to address this question, the resulting data have provided mixed answers and the need for empiric combination therapy in all critically ill patients remains controversial.

Despite recent data from trials that suggest EGDT is no better than usual care, the evolution of care for septic patients continues to improve. However, challenges re­main, particularly with drug-resistant pathogens and the relative dearth of new agents. Fortunately, ongoing clin­ical trials will continue to shed light on areas of contro­versy in this most recent iteration of the guidelines, and certainly there is promise in the progress being made.

Updates to the Definition of Sepsis from 2012 to 2016
Dr. Burchette graduated from Gatton College of Pharmacy in 2010 before completing 2 years of postgraduate residency. She has been a faculty member for 5 years, with a didactic emphasis in pulmonary and critical care PharmD coursework. Clinically, she works in the acute care setting with an academic family medicine team. She is an active member of SIDP.

Dr. Cluck is an assistant professor in the Department of Pharmacy Practice at East Tennessee State University (ETSU) Gatton College of Pharmacy. He maintains a clinical pharmacy practice in infectious diseases at Johnston Memorial Hospital in Abingdon, Virginia, as well as a weekly outpatient HIV clinic with the ETSU HIV Center of Excellence. He is also an active member of SIDP, ACCP, ASHP, IDSA, and AAHIVM.

References:
  1. Damiani E, Donati A, Serafini G, et al. Effect of performance improvement programs on compliance with sepsis bundles and mortality: a systematic review and meta-analysis of observational studies. PLoS One. 2015;10(5):e0125827. doi: 10.1371/journal.pone.0125827.
  2. Rhodes A, Evans L, Alhazzani W, et al. Surviving Sepsis Campaign: international guidelines for management of sepsis and septic shock: 2016. Crit Care Med. 2017;45(3):486-552. doi:10.1097/CCM.0000000000002255.
  3. Rivers E, Nguyen B, Havstad S, et al; Early Goal-Directed Therapy Collaborative Group. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med. 2001;345(19):1368-1377.
  4. Peake SL, Delaney A, Bailey M, et al; ARISE Investigators; ANZICS Clinical Trials Group. Goal-directed resuscitation for patients with early septic shock. N Engl J Med. 2014;371(16):1496-1506. doi: 10.1056/NEJMoa1404380.
  5. Yealy DM, Kellum JA, Huang DT, et al; ProCESS Investigators. A randomized trial of protocol-based care for early septic shock. N Engl J Med. 2014;370(18):1683-1693. doi: 10.1056/NEJMoa1401602.
  6. Mouncey PR, Osborn TM, Power GS, et al; ProMISe Trial Investigators. Trial of early, goal-directed resuscitation for septic shock. N Engl J Med. 2015;372(14):1301-1311. doi: 10.1056/NEJMoa1500896.
  7. Cecconi M, De Backer D, Antonelli M, et al. Consensus on circulatory shock and hemodynamic monitoring. Task force of the European Society of Intensive Care Medicine. Intensive Care Med. 2014;40(12):1795-1815. doi: 10.1007/s00134-014-3525-z.
  8. Eskesen TG, Wetterslev M, Perner A. Systematic review including re-analyses of 1148 individual data sets of central venous pressure as a predictor of fluid responsiveness. Intensive Care Med. 2016;42(3):324-332. doi: 10.1007/s00134-015-4168-4.
  9. Cecconi M, Hofer C, Teboul JL, et al; FENICE Investigators; ESICM Trial Group. Fluid challenges in intensive care: the FENICE study: a global inception cohort study. Intensive Care Med. 2015;41(9):1529-1537;1737-1738. doi: 10.1007/s00134-015-3850-x.
  10. Kumar A, Roberts D, Wood KE, et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med. 2006;34(6):1589-1596.
  11. Ferrer R, Martin-Loeches I, Phillips G, et al. Empiric antibiotic treatment reduces mortality in severe sepsis and septic shock from the first hour: results from a guideline-based performance improvement program. Crit Care Med. 2014;42(8):1749-1755. doi: 10.1097/CCM.0000000000000330.
  12. Pollack LA, van Santen KL, Weiner LM, Dudeck MA, Edwards JR, Srinivasan A. Antibiotic stewardship programs in US acute care hospitals: findings from the 2014 National Healthcare Safety Network Annual Hospital Survey. Clin Infect Dis. 2016;63(4):443-449. doi: 10.1093/cid/ciw323.
  13. Kumar A, Ellis P, Arabi Y, et al; Cooperative Antimicrobial Therapy of Septic Shock Database Research Group. Initiation of inappropriate antimicrobial therapy results in a fivefold reduction of survival in human septic shock. Chest. 2009;136(5):1237-1248. doi: 10.1378/chest.09-0087.
  14. Paul M, Benuri-Silbiger I, Soares-Weiser K, Leibovici L. Beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for sepsis in immunocompetent patients: systematic review and meta-analysis of randomised trials. BMJ. 2004;328(7441):668. Review.
  15. Dellinger RP, Levy MM, Rhodes A, et al; Surviving Sepsis Campaign Guidelines Committee Including the Pediatric Subgroup. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med. 2013;41(2):580-637.
  16. Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, Bellomo R, Bernard GR, Chiche J, Coopersmith CM, Hotchkiss RS, Levy MM, Marshall JC, Martin GS, Opal SM, Rubenfeld GD, van der Poll T, Vincent J, Angus DC. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016;315(8):801-810.


Advocacy and Research Foundation Partners
FEATURED
We break down our top HIV news stories of 2017. Did you read them all?
x